The Manila Times

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxa…

IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside ...
Yahoo

Alpha cells produce GLP-1, like Ozempic drugs, study finds

Add Yahoo as a preferred source to see more of our stories on Google. Alpha cells in the pancreas produce GLP-1, reshaping our understanding of blood sugar control and diabetes care. (CREDIT: ...
Seeking Alpha

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic ...

- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation ...
Business Wire

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel ...
Cure Today

Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell Lymphoma

Cema-cel demonstrated a 67% overall response rate and 58% complete response rate in relapsed/refractory large B-cell lymphoma patients. The phase 1 ALPHA/ALPHA2 study reported a median response ...
Morningstar

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases ...